The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.

Détails

ID Serval
serval:BIB_016DC9095A70
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review.
Périodique
Academic radiology
Auteur(s)
Treglia G., Annunziata S., Sobic-Saranovic D., Bertagna F., Caldarella C., Giovanella L.
ISSN
1878-4046 (Electronic)
ISSN-L
1076-6332
Statut éditorial
Publié
Date de publication
05/2014
Peer-reviewed
Oui
Volume
21
Numéro
5
Pages
675-684
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
To provide an updated evidence-based review of the literature on the role of fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) or PET/computed tomography (PET/CT) in patients with sarcoidosis.
A comprehensive literature search of PubMed/MEDLINE, Scopus, and Embase databases was conducted to find relevant published articles on FDG-PET or PET/CT in patients with sarcoidosis. Only those studies that satisfied all the following criteria were included: (1) FDG-PET or PET/CT performed in patients with histologically confirmed sarcoidosis, (2) sample size of at least 10 patients, and (3) whole-body PET studies performed. Information was collected concerning basic study, patient characteristics, and technical aspects. The main findings of the articles included have been described.
Reviewing titles and abstracts, 21 articles were selected. The role of FDG-PET or PET/CT was analyzed in assessing disease extent and activity and in treatment response evaluation. Comparison with other tracers had also been investigated. Recent studies evaluated the influence of these methods in the clinical management and their role as predictive tools in patients with sarcoidosis.
FDG-PET and PET/CT seem to be useful in staging, evaluating disease activity, and monitoring treatment response in patients with sarcoidosis. PET appears to have higher diagnostic accuracy compared to Gallium-67-citrate scintigraphy. Conversely, there is not enough evidence about the use of other PET tracers in patients with sarcoidosis. FDG-PET and PET/CT seem to have a role as predictive tools and may influence the clinical management in patients with sarcoidosis, but more studies are needed in this regard.

Mots-clé
Evidence-Based Medicine, Fluorodeoxyglucose F18, Humans, Image Enhancement/methods, Multimodal Imaging/methods, Positron-Emission Tomography/methods, Radiopharmaceuticals, Reproducibility of Results, Sarcoidosis/diagnosis, Sensitivity and Specificity, Tomography, X-Ray Computed/methods, Positron emission tomography, fluorodeoxyglucose, sarcoidosis
Pubmed
Web of science
Création de la notice
20/08/2017 19:22
Dernière modification de la notice
03/03/2018 13:14
Données d'usage